Telix Pharmaceuticals Ltd. (TLX)
9.57
+0.31
(+3.35%)
USD |
NASDAQ |
Oct 29, 11:41
Telix Pharmaceuticals Enterprise Value : 3.079B for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 3.079B |
| October 27, 2026 | 3.001B |
| October 26, 2026 | 2.987B |
| October 23, 2026 | 3.041B |
| October 22, 2026 | 3.174B |
| October 21, 2026 | 3.340B |
| October 20, 2026 | 3.724B |
| October 19, 2026 | 3.582B |
| October 16, 2026 | 3.565B |
| October 15, 2026 | 3.524B |
| October 14, 2026 | 3.551B |
| October 13, 2026 | 3.643B |
| October 12, 2026 | 3.769B |
| October 09, 2026 | 3.741B |
| October 08, 2026 | 3.673B |
| October 07, 2026 | 3.711B |
| October 06, 2026 | 3.595B |
| October 05, 2026 | 3.629B |
| October 02, 2026 | 3.517B |
| October 01, 2026 | 3.575B |
| September 30, 2026 | 3.660B |
| September 29, 2026 | 3.786B |
| September 28, 2026 | 3.881B |
| September 25, 2026 | 3.823B |
| September 24, 2026 | 3.775B |
| Date | Value |
|---|---|
| September 23, 2026 | 3.762B |
| September 22, 2026 | 3.993B |
| September 21, 2026 | 3.775B |
| September 18, 2026 | 4.210B |
| September 17, 2026 | 4.181B |
| September 16, 2026 | 3.952B |
| September 15, 2026 | 4.292B |
| September 14, 2026 | 3.935B |
| September 11, 2026 | 3.769B |
| September 10, 2026 | 3.976B |
| September 09, 2026 | 4.125B |
| September 08, 2026 | 4.003B |
| September 04, 2026 | 3.989B |
| September 03, 2026 | 3.921B |
| September 02, 2026 | 3.823B |
| September 01, 2026 | 3.619B |
| August 31, 2026 | 3.701B |
| August 28, 2026 | 3.769B |
| August 27, 2026 | 3.797B |
| August 26, 2026 | 3.714B |
| August 25, 2026 | 3.904B |
| August 24, 2026 | 3.901B |
| August 21, 2026 | 3.782B |
| August 20, 2026 | 4.153B |
| August 19, 2026 | 4.051B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Mesoblast Ltd. | 1.781B |
| Immutep Ltd. | -- |
| CSL Ltd. | -- |
| Ceryvyn Therapeutics Ltd. | -- |
| Propanc Biopharma, Inc. | 6.663M |
Enterprise Value Related Metrics
| Earnings Yield | 0.98% |
| Normalized Earnings Yield | 0.5705 |